VVM
JBIO

Versant Venture Management’s Jade Biosciences JBIO Stock Holding History

Versant Venture Management’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22M Sell
991,783
-534,037
-35% -$11.1M 13.55% 3
2026
Q1 		$21.4M Hold
1,525,820
– – 15.16% 4
2025
Q4 		$23.5M Hold
1,525,820
– – 15.59% 3
2025
Q3 		$13.2M Hold
1,525,820
– – 6.2% 3
2025
Q2 		$15.2M Buy
+1,525,820
New +$51.9M 18.56% 3

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Versant Venture Management's JBIO Position: Q2 2026 in Review

Versant Venture Management reduced its Jade Biosciences (JBIO) stake by 35% in Q2 2026, selling an estimated $11.1M and leaving 991,783 shares worth $22M. The position accounts for 13.55% of the portfolio, ranked #3.

Versant Venture Management first reported a position in JBIO in Q2 2025 and has held it in 5 quarters since. The position peaked at $23.5M in Q4 2025. 153 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • Versant Venture Management held 991,783 shares of Jade Biosciences worth $22M as of Q2 2026.
  • Versant Venture Management sold 534,037 Jade Biosciences shares in Q2 2026, an estimated $11.1M.
  • Jade Biosciences made up 13.55% of Versant Venture Management's portfolio in Q2 2026, its #3 holding.
  • Versant Venture Management first reported a position in Jade Biosciences in Q2 2025 and has held it in 5 quarters since.
  • Versant Venture Management's Jade Biosciences position peaked at $23.5M in Q4 2025.
  • 153 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on Versant Venture Management's 13F filing for Q2 2026, filed 12 Aug 2026.